Compare RECT & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RECT | AKTX |
|---|---|---|
| Founded | 1997 | N/A |
| Country | Singapore | United States |
| Employees | 111 | 5 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.1M | 18.2M |
| IPO Year | N/A | 2014 |
| Metric | RECT | AKTX |
|---|---|---|
| Price | $1.19 | $9.76 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $33.50 |
| AVG Volume (30 Days) | 9.7K | ★ 81.5K |
| Earning Date | 03-20-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.74 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.96 | $0.12 |
| 52 Week High | $4.98 | $29.32 |
| Indicator | RECT | AKTX |
|---|---|---|
| Relative Strength Index (RSI) | 48.03 | 46.71 |
| Support Level | $1.01 | $0.32 |
| Resistance Level | $1.30 | $29.32 |
| Average True Range (ATR) | 0.10 | 1.66 |
| MACD | 0.00 | -0.52 |
| Stochastic Oscillator | 52.01 | 18.56 |
Rectitude Holdings Ltd is principally involved in the provision of safety equipment, encompassing essential items such as personal protective clothing, hand gloves, safety footwear, and personal fall arrest systems (a system used to arrest an employee in a fall from a walking-working surface, usually consisting of a body harness, anchorage, and connector), portable fire extinguishers and traffic products such as rubber speed humps, wheel stops and wheel chocks. Additionally the company has added auxiliary products such as industrial hardware tools and electrical hardware required for construction sites.
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) built around novel, proprietary payloads utilizing powerful biology to attack cancer. Its payload, PH1, targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and growth. Its product pipeline is AKTX-101, which targets the Trop2 receptor on cancer cells and, with a proprietary linker, enables it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. and AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen expressed across multiple solid tumors.